SOON-SHIONG PATRICK 4
4 · ImmunityBio, Inc. · Filed Apr 2, 2026
Research Summary
AI-generated summary of this filing
ImmunityBio (IBRX) Founder Patrick Soon-Shiong Converts Note to 4.6M Shares
What Happened
- Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific & Medical Officer of ImmunityBio (IBRX), acquired 4,606,596 shares on March 31, 2026 by converting a derivative security (a promissory note). The Form 4 reports the conversion at $5.43 per share, for a total value of $24,999,996 (footnote clarifies a conversion price of $5.427/share and that Nant Capital elected to convert $25,000,000 of principal into shares).
Key Details
- Transaction date: March 31, 2026; Conversion price reported: $5.43/share (footnote: $5.427/share).
- Shares acquired: 4,606,596; Reported value: $24,999,996.
- Shares owned after transaction: Not specified in the provided filing excerpt — see the full Form 4 for post-transaction beneficial ownership totals.
- Notable footnotes: Shares were issued to Nant Capital, LLC (an investment vehicle related to the reporting person). Multiple affiliated entities (e.g., Cambridge Equities, NantBio, CalCap, NantWorks and related vehicles) are referenced in the filing and may affect beneficial ownership attribution.
- Reporting status: Filed April 2, 2026 for a March 31, 2026 conversion (no late-filing flag shown in the excerpt provided).
Context
- This was a conversion of debt into equity (not an open-market purchase or option exercise sold for cash). The conversion right arose under a promissory note that allowed Nant Capital to convert principal into common stock between Dec 10, 2024 and Dec 31, 2027; the filing reports exercise of that conversion right.
- As a ~10% owner and company founder/executive, Soon-Shiong’s transactions are significant for ownership structure but do not necessarily signal routine executive buying/selling motives. For full ownership impact, review the complete Form 4 for aggregated holdings across the affiliated entities listed in the footnotes.
Insider Transaction Report
Form 4
SOON-SHIONG PATRICK
DirectorSee remarks10% Owner
Transactions
- Conversion
Common Stock
[F1]2026-03-31$5.43/sh+4,606,596$24,999,996→ 251,018,873 total(indirect: See footnote) - Conversion
Second Amended and Restated Convertible Promissory Note
[F9][F1]2026-03-31(indirect: See footnote)Exercise: $5.43From: 2024-12-10Exp: 2027-12-31→ Common Stock
Holdings
- 29,757,911
Common Stock
- 261,705,814(indirect: See footnote)
Common Stock
[F2] - 8,383,414(indirect: See footnote)
Common Stock
[F3] - 7,976,159(indirect: See footnte)
Common Stock
[F4] - 5,618,326(indirect: See footnote)
Common Stock
[F5] - 9,986,920(indirect: See footnote)
Common Stock
[F6] - 47,557,934(indirect: See footnote)
Common Stock
[F7] - 32,606,985(indirect: See footnote)
Common Stock
[F8]
Footnotes (9)
- [F1]Shares held by Nant Capital, LLC, an investment vehicle of the Reporting Person.
- [F2]Shares held by Cambridge Equities, LP ("Cambridge Equities"). MP 13 Ventures, LLC ("MP 13 Ventures") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The Reporting Person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities.
- [F3]Shares held by NantBio, Inc. ("NantBio"). NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the shares held by NantBio. The Reporting Person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the shares held by NantBio.
- [F4]Shares held by California Capital Equity, LLC ("CalCap"). The Reporting Person owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap.
- [F5]Shares held by the Chan Soon-Shiong Family Foundation, an exempt corporation organized under the laws of the State of Delaware (the "Foundation"). The Foundation has the sole power to vote and direct the disposition of all shares directly owned by the Foundation, except to the extent it may be deemed to share such power with the Reporting Person by virtue of the Reporting Person's control over the Foundation. The Reporting Person serves as Chairman of the Foundation.
- [F6]Shares held by NantWorks. CalCap directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The Reporting Person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks.
- [F7]Shares held by NantMobile, LLC ("NantMobile"). NantWorks is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The Reporting Person is the Chief Executive Officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile.
- [F8]Shares held by NantCancerStemCell, LLC ("NantCancerStemCell"). NantBio is the majority stockholder and an affiliate of NantCancerStemCell and may be deemed to have beneficial ownership of the securities held by NantCancerStemCell. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The Reporting Person is the Chief Executive Officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates.
- [F9]Nant Capital has the right at any time after December 10, 2024 and on or before December 31, 2027 to convert all or a portion of the outstanding principal amount of this Second Amended and Restated Promissory Note, as amended January 23, 2026, into fully paid and nonassessable shares of the Issuer's common stock at a price per share equal to $5.427. On March 31, 2026, Nant Capital delivered notice to the Issuer electing to convert outstanding principal in the amount of $25,000,000 into 4,606,596 shares of the Issuer's common stock.
Signature
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity and Manager of Nant Capital|2026-04-02